GlaxoSmithKline and Genmab seek European marketing authorisation of Arzerra™ (ofatumumab) in advanced stage blood cancer

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Personalized Treatment Strategies for HER2-Positive Gastroesophageal Adenocarcinoma

This article discusses evolving strategies for personalized treatment of HER2-positive gastroesophageal adenocarcinoma (GEA). It features in

EMA begins phased review of daraxonrasib for metastatic pancreatic cancer treatment

The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, a medicine for metastatic pancreatic cancer. This acceler

Phase Ib/IIa Open-label Study, to Evaluate Safety, Tolerability, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Gastric or Gastro-esophageal (GEJ) Adenocarcinoma

Avacta Therapeutics presents platform-validating data for faridoxorubicin in salivary gland cancer at BIO International Conference

Avacta Therapeutics announced platform-validating clinical data for faridoxorubicin (AVA6000), a tumor-activated oncology drug using its pre

ME Fund seeks support for ResetME trial testing daratumumab as potential ME/CFS treatment

The ME Fund (ME-fondet), a Norwegian non-profit, is raising funds for the ResetME trial — a larger, controlled study of daratumumab (a monoc